Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhTPO for Thrombocytopenia Prevention in Lymphoma Patients Receiving DHAP
NCT00039910Phase 3Completed
- Sponsor
- Pfizer
- Start
- Jul 2000
- Modality
- Cytokines & Interferons
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial in Thrombocytopenia comparing rhTPO with Placebo (2 arms). Primary endpoint: Cumulative proportion of patients who experience severe chemotherapy-induced thrombocytopenia. Started Jul 2000; status: completed.
02
Drugs
recombinant human thrombopoietin
03
Conditions
Thrombocytopenia
Beyond the preview
Go deeper on NCT00039910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00039910.